Coutaneous drug reactions;Unerwünschte arzneireaktionen an der haut

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 50, 2007, Pages 2685-2694

  Rupec, R A ^a   Boneberger, S ^a   Ruzicka, Thomas ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Acute generalized exanthematous pustulosis; Adverse drug reaction; Drug rash with eosinophilia and systemic symptoms; Exanthema; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CEFTRIAXONE; CERTOPARIN; CHLORPROPAMIDE; DALTEPARIN; DANAPAROID; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FONDAPARINUX; HEPARIN; IMATINIB; METHYLDOPA; MINOCYCLINE; NADROPARIN; NEVIRAPINE; PENICILLAMINE; PENTOSAN POLYSULFATE; PHENOBARBITAL; QUINIDINE; QUININE; REVIPARIN; SALAZOSULFAPYRIDINE; STREPTOMYCIN; SULFAMETHOXAZOLE; THIAZIDE DIURETIC AGENT; TOLAZAMIDE; UNINDEXED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRINOLYTIC AGENT;

ACNE; ADULT; ALLERGIC RASH; ALLERGY TEST; ANTICOAGULATION; BLOOD EXAMINATION; CASE REPORT; DRESS SYNDROME; DRUG EFFECT; DRUG INDUCED DISEASE; ECZEMA; HUMAN; LICHEN PLANUS; LICHENOID ERUPTION; MACULOPAPULAR RASH; NEUTROPHIL; PHOTOALLERGY; PHOTOTOXICITY; RASH; REVIEW; STEVENS JOHNSON SYNDROME; THROMBOPHLEBITIS; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; DRUG ERUPTION; EOSINOPHILIA; FEMALE; FEVER; LYMPHATIC SYSTEM DISEASE; MIDDLE AGED; PATHOLOGY; SYNDROME;

ACNEIFORM ERUPTIONS; DALTEPARIN; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EOSINOPHILIA; EXANTHEMA; FEMALE; FEVER; FIBRINOLYTIC AGENTS; HUMANS; LICHENOID ERUPTIONS; LYMPHATIC DISEASES; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; STEVENS-JOHNSON SYNDROME; SYNDROME; THROMBOPHLEBITIS;

EID: 38049056314     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993120     Document Type: Review

References (35)

1. Allam JP, Paus T, Reichel C, Bieber T, Novak N. DRESS syndrome associated with carbamazepine and phenytoin. Eur J Dermatol 2004; 14: 339-342
2. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-3363
3. Brockow K, Romano A, Blanca M et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51
4. Brooks SL. Lichenoid reaction of oral mucosa and skin to methyldopa. J Oral Med 1982; 37: 42-44
5. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357: 514-515
6. Calista D, Morri M. Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. Int J Dermatol 2004; 43: 562-564
7. de Groot AC. Patch testing. 2nd ed. Amsterdam: Elsevier, 1994
8. Descamps V, Valance A, Edlinger C et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-304
9. Duran I, Hotte SJ, Hirte H et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 4849-4857
10. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006; 17: 1227-1229
11. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33: 551-573
12. Guenther CH, Wozel G, Laske J, Aschoff R, Meurer M. Macular exanthema due to fumaric acid esters. Ann Pharmacother 2003; 37: 234-236
13. Guijarro Guijarro B, Lopez Sanchez AF. Lichenoid reaction caused by Clopidogrel, a new anti-platelet drug. Med Oral 2003; 8: 33-37
14. Gutzmer R, Werfel T, Mao R, Kapp A, Elsner J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153: 849-851
15. Herfs H, Schirren CG, Przybilla B, Plewig G. Das "Baboon-Syndrom". Eine besondere Manifestation einer hämatogenen Kontaktreaktion. Hautarzt 1993; 44: 466-469
16. Jamali M, El Ouazzani T, Zouhair K, Lakhdar H. Carbamazepine hypersensitivity syndrome associated with cytomegalovirus reactivation. Ann Dermatol Venereol 2007; 134: 72-73
17. Komericki P, Grims R, Kranke B, Aberer W. Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol 2007; 57: 718-721
18. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205
19. Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, Delaporte E. Manifestations cutanées observées au cours d'un traitement par anti-TNF a: 11 observations. Ann Dermatol Venereol 2007; 134: 337-342
20. Lim DS, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 2002; 205: 169-171
21. Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007; 25: 1232-1238
22. Litt JZ. Drug eruption reference manual. 12th ed. London and New York: Taylor and Francis, 2006
23. Mittmann N, Chan BC, Knowles S, Shear NH. IVIG for the treatment of toxic epidermal necrolysis. Skin Therapy Lett 2007; 12: 7-9
24. Mockenhaupt M. Schwere Arzneimittelreaktionen der Haut. Klinik und Epidemiologie. Hautarzt 2005; 56: 24-31
25. Organization WH. International drug monitoring: The role of the hospital. In, Technical Report Series No 425. Geneva, Switzerland: World Health Organization, 1966
26. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200
27. Ring J, Darsow U. Idiopathic anaphylaxis. Curr Allergy Asthma Rep 2002; 2: 40-45
28. Roujeau JC, Bioulac-Sage P, Bourseau C et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127: 1333-1338
29. Shiohara T, Mizukawa Y. Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol 2007; 17: 201-208
30. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol 2002; 2: 317-323
31. Stern RS. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2000; 136: 410-411
32. Van Doorn R, Kirtschig G, Scheffer E, Stoof TJ, Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598-601
33. Yasuda S, Mizuno N, Kawabe Y, Sakakibara S. Photosensitive lichenoid reaction accompanied by nonphotosensitive subacute prurigo caused by carbamazepine. Photodermatol 1988; 5: 206-210
34. Zoller A, Schad SG, Gross GE. Erlotinib-associated skin reactions - case report and proposal for classification. Br J Dermatol 2006; 155: 1293-1295
35. Zürcher K, Krebs A. Cutaneous drug reactions: an integral synopsis of today's systemic drugs. 2nd ed. Freiburg i. Br.: Karger, 1998